NCT06787807

Brief Summary

The expression of proteins in the blood of obese individuals is different from the expression of proteins in healthy individuals, and is also different in individuals after bariatric surgery. Therefore, this research aims to better understand protein expression in patients indicated for surgical treatment of obesity, evaluating the pre-operative and post-operative status. The objective of this research is to better understand protein expression in patients indicated for surgical treatment of obesity, evaluating the pre-operative and post-surgery status.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
103

participants targeted

Target at P50-P75 for not_applicable obesity

Timeline
Completed

Started Jun 2025

Shorter than P25 for not_applicable obesity

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 16, 2025

Completed
6 days until next milestone

First Posted

Study publicly available on registry

January 22, 2025

Completed
5 months until next milestone

Study Start

First participant enrolled

June 10, 2025

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 9, 2025

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2025

Completed
Last Updated

January 22, 2025

Status Verified

January 1, 2025

Enrollment Period

3 months

First QC Date

January 16, 2025

Last Update Submit

January 16, 2025

Conditions

ObesityColon CancerThyroid CancerEsophageal CancerPancreatic CancerGastric CancerPotmenopausal Breast CancerEndometrial CancerLiver CancerGallbladder CancerProstate CancerOvarianKidney CancerMultiple MyelomaMeningiomaBreast CancerOvarian Cancer

Keywords

obesitycancerbariatric surgeryproteomicsbiomarkersmass spectrometry

Outcome Measures

Primary Outcomes (1)

  • Number of patients with reduced initially upregulated oncogenic proteins

    reduction of proteins potentially involved in oncogenic metabolic pathways, initially upregulated in the context of obesity

    1 year after bariatric surgery

Study Arms (7)

women with insulin resistance

EXPERIMENTAL

An analysis was made of patients with severe steatosis, among patients undergoing bariatric surgery

Procedure: bariatric surgery

patients with severe steatosis

EXPERIMENTAL

An analysis was made of patients with severe steatosis, among patients undergoing bariatric surgery

Procedure: bariatric surgery

General patients with insulin resistance

EXPERIMENTAL

An analysis was made of patients, among men and women, with insulin resistance, among patients undergoing bariatric surgery

Procedure: bariatric surgery

Patients with above average CRP

EXPERIMENTAL

An analysis was carried out of patients with CRP above the average, among patients undergoing bariatric surgery

Procedure: bariatric surgery

Patients with grade 1 obesity

EXPERIMENTAL

An analysis was made of patients with grade 1 obesity, among patients undergoing bariatric surgery

Procedure: bariatric surgery

Patients with grade 2 obesity

EXPERIMENTAL

An analysis was made of patients with grade 2 obesity, among patients undergoing bariatric surgery

Procedure: bariatric surgery

Patients with grade 3 obesity

EXPERIMENTAL

An analysis was made of patients with grade 3 obesity, among patients undergoing bariatric surgery

Procedure: bariatric surgery

Interventions

bariatric surgeryPROCEDURE

sleeve gastrectomy

Also known as: sleeve gastrectomy
General patients with insulin resistancePatients with above average CRPPatients with grade 1 obesityPatients with grade 2 obesityPatients with grade 3 obesitypatients with severe steatosiswomen with insulin resistance

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patients over 18 years of age with a BMI above 35 kg/m² associated with comorbidity or BMI above 40 kg/m² without comorbidities,

You may not qualify if:

  • Patients with a previous history of cancer;
  • Underage patients
  • Patients with other diseases predisposing to the development of cancer: cirrhosis, ulcerative colitis, Barrett's esophagus, etc.
  • Patients who have previously undergone bariatric surgery;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital das clínicas da UFPE

Recife, Pernambuco, 50670901, Brazil

Location

MeSH Terms

Conditions

ObesityColonic NeoplasmsThyroid NeoplasmsEsophageal NeoplasmsPancreatic NeoplasmsStomach NeoplasmsEndometrial NeoplasmsLiver NeoplasmsGallbladder NeoplasmsProstatic NeoplasmsKidney NeoplasmsMultiple MyelomaMeningiomaBreast NeoplasmsOvarian NeoplasmsNeoplasms

Interventions

Bariatric Surgery

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsColorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesEndocrine Gland NeoplasmsHead and Neck NeoplasmsEndocrine System DiseasesThyroid DiseasesEsophageal DiseasesPancreatic DiseasesStomach DiseasesUterine NeoplasmsGenital Neoplasms, FemaleUrogenital NeoplasmsUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital DiseasesLiver DiseasesBiliary Tract NeoplasmsBiliary Tract DiseasesGallbladder DiseasesGenital Neoplasms, MaleGenital Diseases, MaleProstatic DiseasesMale Urogenital DiseasesUrologic NeoplasmsKidney DiseasesUrologic DiseasesNeoplasms, Plasma CellNeoplasms by Histologic TypeHemostatic DisordersVascular DiseasesCardiovascular DiseasesParaproteinemiasBlood Protein DisordersHematologic DiseasesHemic and Lymphatic DiseasesHemorrhagic DisordersLymphoproliferative DisordersImmunoproliferative DisordersImmune System DiseasesNeoplasms, Nerve TissueNeoplasms, Vascular TissueMeningeal NeoplasmsCentral Nervous System NeoplasmsNervous System NeoplasmsNervous System DiseasesBreast DiseasesSkin DiseasesSkin and Connective Tissue DiseasesOvarian DiseasesAdnexal DiseasesGonadal Disorders

Intervention Hierarchy (Ancestors)

BariatricsObesity ManagementTherapeuticsSurgical Procedures, Operative

Study Officials

  • Álvaro B Ferraz, Doctor

    UFPE

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Luiz Henrique A Bandeira, Medicine student

CONTACT

5581987082731luiz.bandeira@ufpe.br

Júlia M Lins, medicine student

CONTACT

5581996906749julia.lins@upe.br

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Full professor and head of the general surgery service at UFPE

Study Record Dates

First Submitted

January 16, 2025

First Posted

January 22, 2025

Study Start

June 10, 2025

Primary Completion

September 9, 2025

Study Completion

December 1, 2025

Last Updated

January 22, 2025

Record last verified: 2025-01

Locations

BR(1)